Evaluating the Antibacterial and Antivirulence Activities of Floxuridine against <i>Streptococcus suis</i>
<i>Streptococcus suis</i> is an emerging zoonotic pathogen that can cause fatal diseases such as meningitis and sepsis in pigs and human beings. The overuse of antibiotics is leading to an increased level of resistance in <i>S. suis</i>, and novel antimicrobial agents or anti...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/18/14211 |
| Summary: | <i>Streptococcus suis</i> is an emerging zoonotic pathogen that can cause fatal diseases such as meningitis and sepsis in pigs and human beings. The overuse of antibiotics is leading to an increased level of resistance in <i>S. suis</i>, and novel antimicrobial agents or anti-virulence agents for the treatment of infections caused by <i>S. suis</i> are urgently needed. In the present study, we investigated the antibacterial activity, mode of action and anti-virulence effects of floxuridine against <i>S. suis</i>. Floxuridine showed excessive antibacterial activity against <i>S. suis</i> both in vivo and in vitro; 4 × MIC of floxuridine could kill <i>S. suis</i> within 8 h in a time–kill assay. Meanwhile, floxuridine disrupted the membrane structure and permeability of the cytoplasmic membrane. Molecular docking revealed that floxuridine and SLY can be directly bind to each other. Moreover, floxuridine effectively inhibited the hemolytic capacity and expression levels of the virulence-related genes of <i>S. suis</i>. Collectively, these results indicate that the FDA-approved anticancer drug floxuridine is a promising agent and a potential virulence inhibitor against <i>S. suis</i>. |
|---|---|
| ISSN: | 1661-6596 1422-0067 |